Safety and Effectiveness of Dupilumab in Prurigo Nodularis

J Investig Allergol Clin Immunol. 2021 Apr 20;31(2):162-163. doi: 10.18176/jiaci.0550. Epub 2020 Jun 23.

Author

C Romano¹

Affiliation

¹ Clinical Immunology Outpatient Clinic - Division of Internal Medicine, Department of Advanced Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Naples, Italy.

PMID: 32573461
DOI: 10.18176/jiaci.0550

No abstract available

Keywords: Congestive heart failure; Dupilumab; Prurigo nodularis; Safety.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Female
Heart Failure / drug therapy*
Humans
Immunoglobulin E / blood
Interleukin-4 Receptor alpha Subunit / immunology*
Middle Aged
Prurigo / drug therapy*
Pruritus
Skin / pathology*
Th2 Cells / immunology*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Interleukin-4 Receptor alpha Subunit
Immunoglobulin E
dupilumab